Asset profile

Iberdomide

Small molecule

Phase 3underway

Evidence outlook · registrational

Multiple Myeloma: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-04.

How the evidence outlook works ↗

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
September 2026 (1)
Phase 1/2Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-09-29 · NCT05392946 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (6)
April 2027 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-26 · NCT05354557 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 2Smoldering Plasma Cell MyelomaRecruiting
Est. primary completion 2027-09-01 · NCT04776395 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT04392037 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT06107738 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (5)
March 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-05-01 · NCT06232044 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-12 · NCT06216158 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (5)
March 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-03-15 · NCT05827016 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-07-01 · NCT07601100 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2029-12 · NCT05527340 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT06518551 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
January 2030 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-01-01 · NCT04998786 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
April 2031 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2031-04-01 · NCT06785415 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
November 2032 (1)
Phase 2Smouldering MyelomaRecruiting
Est. primary completion 2032-11 · NCT06762769 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (1)
October 2033 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.